To investigate whether binding of trastuzumab to HER2 inhibits the proliferation of HER2-positive breast cancer cells, we treated SKBR3 and BT474 cell lines with 10 μg/mL trastuzumab for 5 days and monitored the cell proliferation levels by MTT assay. The gene discussed is ERBB2; the disease is breast cancer.